Effect of siRNA silencing of inducible co-stimulatory molecule on myocardial cell hypertrophy after cardiac infarction in rats.
As the most common cardiac disease, myocardial infarction is followed by hypertrophy of cardiac myocytes and reconstruction of ventricular structure. The up-regulation of a series of factors including metalloproteinases, inflammatory factors, and growth factors after primary infarction lead to the hypertrophy, apoptosis, necrosis, and fibroblast proliferation in cardiac muscle tissues. Recent studies have reported on the potency of small interfering RNA (siRNA) in treating cardiac diseases. We thus investigated the efficacy of inducible co-stimulatory molecule (ICOS)-specific siRNA silencing in myocardial hypertrophy in a cardiac infarction rat model. This cardiac infarction model was prepared by ligating the left anterior descending coronary artery. ICOS-siRNA treatment was administered in parallel with non-sense siRNA. After 18 days, the cross-sectional area of cardiac muscle tissues and the left ventricle weight index were measured, along with ICOS mRNA and protein expression levels, and pathological staining. Compared to those in the control groups, in myocardial infarcted rats, the application of ICOS-siRNA effectively decreased the left ventricle weight index, as well as the surface area of cardiac myocytes. Both mRNA and protein levels of ICOS were also significantly decreased. HE staining was consistent with these results. In conclusion, ICOS-targeted siRNA can effectively silence gene expression of ICOS, and provided satisfactory treatment efficacy for myocardial cell hypertrophy after infarction.
Department of Interventional Medicine, Binzhou Medical College Hospital, Binzhou, China.
W M
WM
Wang
Department of Interventional Medicine, Binzhou Medical College Hospital, Binzhou, China.
Z
Z
Liu
Department of Interventional Medicine, Binzhou Medical College Hospital, Binzhou, China.
G
G
Chen
D000818:Animals; D005786:Gene Expression Regulation / Q000187:drug effects; D015316:Genetic Therapy / Q000379:methods; D006352:Heart Ventricles / Q000473:pathology; D006801:Humans; D006984:Hypertrophy / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D060889:Inducible T-Cell Co-Stimulator Protein / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D009203:Myocardial Infarction / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D051381:Rats
C556695:Icos protein, rat; D060889:Inducible T-Cell Co-Stimulator Protein; D012333:RNA, Messenger; D034741:RNA, Small Interfering